
Damian F J Purcell

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4542927/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Complement regulatory proteins at the feto-maternal interface during human placental development: distribution of CD59 by comparison with membrane cofactor protein(CD46) and decay accelerating factor (CD55). European Journal of Immunology, 1992, 22, 1579-1585.	1.6	142
2	Nanobody cocktails potently neutralize SARS-CoV-2 D614G N501Y variant and protect mice. Proceedings of the National Academy of Sciences of the United States of America, 2021, 118, .	3.3	109
3	Asn 362 in gp120 contributes to enhanced fusogenicity by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with AIDS. Retrovirology, 2007, 4, 89.	0.9	82
4	Expression and reactivation of HIV in a chemokine induced model of HIV latency in primary resting CD4+ T cells. Retrovirology, 2011, 8, 80.	0.9	82
5	Safety and immunogenicity of an MF59-adjuvanted spike glycoprotein-clamp vaccine for SARS-CoV-2: a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Infectious Diseases, The, 2021, 21, 1383-1394.	4.6	82
6	SARS-CoV-2 suppresses IFNβ production mediated by NSP1, 5, 6, 15, ORF6 and ORF7b but does not suppress the effects of added interferon. PLoS Pathogens, 2021, 17, e1009800.	2.1	74
7	A randomized, placebo-controlled phase I trial of DNA prime, recombinant fowlpox virus boost prophylactic vaccine for HIV-1. Aids, 2006, 20, 294-297.	1.0	58
8	Small Interfering RNAs against the TAR RNA Binding Protein, TRBP, a Dicer Cofactor, Inhibit Human Immunodeficiency Virus Type 1 Long Terminal Repeat Expression and Viral Production. Journal of Virology, 2007, 81, 5121-5131.	1.5	58
9	Evaluation of Serological Tests for SARS-CoV-2: Implications for Serology Testing in a Low-Prevalence Setting. Journal of Infectious Diseases, 2020, 222, 1280-1288.	1.9	56
10	Hyperimmune Bovine Colostrum as a Low-Cost, Large-Scale Source of Antibodies with Broad Neutralizing Activity for HIV-1 Envelope with Potential Use in Microbicides. Antimicrobial Agents and Chemotherapy, 2012, 56, 4310-4319.	1.4	50
11	Evaluation in macaques of HIV-1 DNA vaccines containing primate CpG motifs and fowlpoxvirus vaccines co-expressing IFN? or IL-12. Vaccine, 2004, 23, 188-197.	1.7	47
12	Primary HIV-1 R5 isolates from end-stage disease display enhanced viral fitness in parallel with increased gp120 net charge. Virology, 2008, 379, 125-134.	1.1	45
13	Genetic and Functional Analysis of R5X4 Human Immunodeficiency Virus Type 1 Envelope Glycoproteins Derived from Two Individuals Homozygous for the CCR5Δ32 Allele. Journal of Virology, 2006, 80, 3684-3691.	1.5	43
14	The Molecular Biology of HIV Latency. Advances in Experimental Medicine and Biology, 2018, 1075, 187-212.	0.8	43
15	Infrared Based Saliva Screening Test for COVIDâ€19. Angewandte Chemie - International Edition, 2021, 60, 17102-17107.	7.2	42
16	Induction of HIV-1 subtype B and AE-specific neutralizing antibodies in mice and macaques with DNA prime and recombinant gp140 protein boost regimens. Vaccine, 2009, 27, 6605-6612.	1.7	38
17	Reprogrammed CRISPR-Cas13b suppresses SARS-CoV-2 replication and circumvents its mutational escape through mismatch tolerance. Nature Communications, 2021, 12, 4270.	5.8	37
18	Selectively Reduced tat mRNA Heralds the Decline in Productive Human Immunodeficiency Virus Type 1 Infection in Monocyte-Derived Macrophages. Journal of Virology, 2002, 76, 12611-12621.	1.5	34

DAMIAN F J PURCELL

#	Article	IF	CITATIONS
19	Both Linear and Discontinuous Ribosome Scanning Are Used for Translation Initiation from Bicistronic Human Immunodeficiency Virus Type 1 env mRNAs. Journal of Virology, 2007, 81, 4664-4676.	1.5	33
20	Simultaneous evaluation of antibodies that inhibit SARS-CoV-2 variants via multiplex assay. JCI Insight, 2021, 6, .	2.3	33
21	A point-of-care lateral flow assay for neutralising antibodies against SARS-CoV-2. EBioMedicine, 2021, 74, 103729.	2.7	29
22	Human T-cell lymphotropic virus type-1: a lifelong persistent infection, yet never truly silent. Lancet Infectious Diseases, The, 2021, 21, e2-e10.	4.6	28
23	HIV latency reversing agents act through Tat post translational modifications. Retrovirology, 2018, 15, 36.	0.9	24
24	Gene expression signatures of circulating human type 1, 2, and 3 innate lymphoid cells. Journal of Allergy and Clinical Immunology, 2019, 143, 2321-2325.	1.5	24
25	Multiply spliced HIV RNA is a predictive measure of virus production ex vivo and in vivo following reversal of HIV latency. EBioMedicine, 2021, 65, 103241.	2.7	24
26	Efficient transcription through an intron requires the binding of an Sm-type U1 snRNP with intact stem loop II to the splice donor. Nucleic Acids Research, 2010, 38, 3041-3053.	6.5	23
27	Identification of Native and Posttranslationally Modified HLAâ€B*57:01â€Restricted HIV Envelope Derived Epitopes Using Immunoproteomics. Proteomics, 2018, 18, e1700253.	1.3	23
28	Evaluation of 6 Commercial SARS-CoV-2 Serology Assays Detecting Different Antibodies for Clinical Testing and Serosurveillance. Open Forum Infectious Diseases, 2021, 8, ofab239.	0.4	23
29	Antiâ€ <scp>HIV</scp> â€1 antibodyâ€dependent cellular cytotoxicity mediated by hyperimmune bovine colostrum <scp>I</scp> g <scp>G</scp> . European Journal of Immunology, 2012, 42, 2771-2781.	1.6	22
30	Evolution of DC-SIGN use revealed by fitness studies of R5 HIV-1 variants emerging during AIDS progression. Retrovirology, 2008, 5, 28.	0.9	21
31	Enhanced CD4+ cellular apoptosis by CCR5-restricted HIV-1 envelope glycoprotein variants from patients with progressive HIV-1 infection. Virology, 2010, 396, 246-255.	1.1	20
32	HIV-1-Based Virus-like Particles that Morphologically Resemble Mature, Infectious HIV-1 Virions. Viruses, 2019, 11, 507.	1.5	17
33	Co-Expression of miRNA Targeting the Expression of PERK, but Not PKR, Enhances Cellular Immunity from an HIV-1 Env DNA Vaccine. PLoS ONE, 2011, 6, e18225.	1.1	16
34	Multiplex Droplet Digital PCR Assay for Quantification of Human T-Cell Leukemia Virus Type 1 Subtype c DNA Proviral Load and T Cells from Blood and Respiratory Exudates Sampled in a Remote Setting. Journal of Clinical Microbiology, 2019, 57, .	1.8	15
35	Optimal preparation of SARS-CoV-2 viral transport medium for culture. Virology Journal, 2021, 18, 53.	1.4	15
36	Infrared Based Saliva Screening Test for COVIDâ€19. Angewandte Chemie, 2021, 133, 17239-17244.	1.6	15

DAMIAN F J PURCELL

#	Article	IF	CITATIONS
37	Air-Liquid-Interface Differentiated Human Nose Epithelium: A Robust Primary Tissue Culture Model of SARS-CoV-2 Infection. International Journal of Molecular Sciences, 2022, 23, 835.	1.8	15
38	p30 protein: a critical regulator of HTLV-1 viral latency and host immunity. Retrovirology, 2019, 16, 42.	0.9	13
39	Role of HTLV-1 orf-I encoded proteins in viral transmission and persistence. Retrovirology, 2019, 16, 43.	0.9	13
40	Impact of Hepatitis B Virus Coinfection on Human T-Lymphotropic Virus Type 1 Clonality in an Indigenous Population of Central Australia. Journal of Infectious Diseases, 2019, 219, 562-567.	1.9	13
41	Tat IRES modulator of tat mRNA (TIM-TAM): a conserved RNA structure that controls Tat expression and acts as a switch for HIV productive and latent infection. Nucleic Acids Research, 2020, 48, 2643-2660.	6.5	13
42	Water-Borne Nanocoating for Rapid Inactivation of SARS-CoV-2 and Other Viruses. ACS Nano, 2021, 15, 14915-14927.	7.3	13
43	MYB Elongation Is Regulated by the Nucleic Acid Binding of NFκB p50 to the Intronic Stem-Loop Region. PLoS ONE, 2015, 10, e0122919.	1.1	12
44	Evaluation of virucidal activity of residual quaternary ammonium-treated surfaces on SARS-CoV-2. American Journal of Infection Control, 2022, 50, 325-329.	1.1	11
45	Repeated Vaccination of Cows with HIV Env gp140 during Subsequent Pregnancies Elicits and Sustains an Enduring Strong Env-Binding and Neutralising Antibody Response. PLoS ONE, 2016, 11, e0157353.	1.1	10
46	Trimeric gp120-specific bovine monoclonal antibodies require cysteine and aromatic residues in CDRH3 for high affinity binding to HIV Env. MAbs, 2017, 9, 550-566.	2.6	8
47	Immunogenicity of HIV-1-Based Virus-Like Particles with Increased Incorporation and Stability of Membrane-Bound Env. Vaccines, 2021, 9, 239.	2.1	8
48	The RNA-Binding Proteins SRP14 and HMGB3 Control HIV-1 Tat mRNA Processing and Translation During HIV-1 Latency. Frontiers in Genetics, 2021, 12, 680725.	1.1	7
49	Enhancement of Antibody-Dependent Cellular Cytotoxicity and Phagocytosis in Anti-HIV-1 Human-Bovine Chimeric Broadly Neutralizing Antibodies. Journal of Virology, 2021, 95, e0021921.	1.5	7
50	Application of a case–control study design to investigate genotypic signatures of HIV-1 transmission. Retrovirology, 2012, 9, 54.	0.9	5
51	Functional properties and sequence variation of HTLV-1 p13. Retrovirology, 2020, 17, 11.	0.9	5
52	The Efficacy of Common Household Cleaning Agents for SARS-CoV-2 Infection Control. Viruses, 2022, 14, 715.	1.5	5
53	Suppression subtractive hybridization method for the identification of a new strain of murine hepatitis virus from xenografted SCID mice. Archives of Virology, 2015, 160, 2945-2955.	0.9	3
54	Differentiating founder and chronic HIV envelope sequences. PLoS ONE, 2017, 12, e0171572.	1.1	3

DAMIAN F J PURCELL

#	Article	IF	CITATIONS
55	Detection of Chimeric Cellular: HIV mRNAs Generated Through Aberrant Splicing in HIV-1 Latently Infected Resting CD4+ T Cells. Frontiers in Cellular and Infection Microbiology, 2022, 12, 855290.	1.8	3
56	Broad and ultra-potent cross-clade neutralization of HIV-1 by a vaccine-induced CD4 binding site bovine antibody. Cell Reports Medicine, 2022, 3, 100635.	3.3	3
57	Comment on Ultrarapid On-Site Detection of SARS-CoV-2 Infection Using Simple ATR-FTIR Spectroscopy and an Analysis Algorithm: High Sensitivity and Specificity. Analytical Chemistry, 2021, 93, 16974-16976.	3.2	2
58	Liquid Chalk Is an Antiseptic against SARS-CoV-2 and Influenza A Respiratory Viruses. MSphere, 2021, 6, e0031321.	1.3	1
59	Nonhuman primate models for evaluation of SARS-CoV-2 vaccines. Expert Review of Vaccines, 2022, 21, 1055-1070.	2.0	1
60	Chimeric Bovine-V-region and Human-C-region mAbs with Long and Extensively Mutated CDHR3 Domains Bind HIV-1 Env gp140 Trimers, but Not gp120 Monomer. AIDS Research and Human Retroviruses, 2014, 30, A121-A122.	0.5	0
61	Conjugation of an scFab domain to the oligomeric HIV envelope protein for use in immune targeting. PLoS ONE, 2019, 14, e0220986.	1.1	0
62	High Throughput In Vitro Assessment of Latency Reversing Agents on HIV Transcription and Splicing. Journal of Visualized Experiments, 2019, , .	0.2	0